In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Sunesis Pharma (SNSS). The company’s shares closed yesterday at $0.95.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 3.1% and a 47.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Sunesis Pharma is a Moderate Buy with an average price target of $0.50.
See today’s analyst top recommended stocks >>
Based on Sunesis Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6 million. In comparison, last year the company had a GAAP net loss of $6.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
